➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Moodys
Dow
Johnson and Johnson

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRIVIACT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for BRIVIACT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03021018 A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting Not yet recruiting UCB Biopharma S.P.R.L. Phase 2 2017-01-01 The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
NCT03083665 A Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Asian Subjects (>=16 to 80 Years of Age) With Epilepsy Not yet recruiting UCB Biopharma S.P.R.L. Phase 3 2017-07-14 The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in Asian subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.
NCT03250377 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Enrolling by invitation UCB Biopharma S.P.R.L. Phase 3 2017-08-05 The purpose of the study is to evaluate the long-term safety and tolerability of BRV in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BRIVIACT

Condition Name

Condition Name for BRIVIACT
Intervention Trials
Epilepsy 5
Partial Seizures With or Without Secondary Generalization 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for BRIVIACT
Intervention Trials
Epilepsy 5
Seizures 4
Neoplasm Metastasis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for BRIVIACT

Trials by Country

Trials by Country for BRIVIACT
Location Trials
United States 8
Japan 1
Hungary 1
Germany 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for BRIVIACT
Location Trials
Texas 1
Ohio 1
North Carolina 1
New York 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for BRIVIACT

Clinical Trial Phase

Clinical Trial Phase for BRIVIACT
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for BRIVIACT
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 1
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for BRIVIACT

Sponsor Name

Sponsor Name for BRIVIACT
Sponsor Trials
UCB Biopharma S.P.R.L. 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for BRIVIACT
Sponsor Trials
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.